All posts by imreal

Lipedema Foundation Releases Report on Initial Findings of Patient Registry


“While we do not have a diagnostic test and the full range of treatments is unknown, what is clear is that the physical and emotional burden of Lipedema exists for patients for many years before it is first diagnosed or treated,” says Jonathan Kartt, CEO, Lipedema Foundation.

The Lipedema Foundation, the world’s largest funder of Lipedema research, has published initial findings from its patient registry. “Learning By Listening: The LF Registry First Look Report” focuses on the experiences of people who have Lipedema and the challenges that they face living with this chronic medical condition that primarily impacts women.

Lipedema is characterized by a symmetric buildup of adipose tissue (fat) in the legs and arms, often with pain, and at advanced stages, impaired mobility.

In 2019, the Lipedema Foundation launched the LF Registry, an online database to learn more about Lipedema and its impact on individuals, families, clinicians, and researchers. The “First Look Report” analyzes data from the first 521 completed Registry surveys from people who have either been diagnosed with Lipedema or have symptoms that lead them to believe they have the condition.

Lipedema is a widespread but underdiagnosed condition. Currently, there are no diagnostic tests to determine if a patient has Lipedema. The Lipedema Foundation is a non-profit organization, funding research to define, diagnose and develop treatments for Lipedema.

“While we do not have a diagnostic test and the full range of treatments is unknown, what is clear is that the physical and emotional burden of Lipedema exists for patients for many years before it is first diagnosed or treated,” says Jonathan Kartt, Chief Executive Officer of the Lipedema Foundation.

Key findings of the “First Look Report” include:

  • Symptoms often appear during puberty: Almost 58% of participants first noticed Lipedema symptoms between the ages of 10-19 years, most between ages 12 and 14
  • Hormones may play a role: 10% of participants experienced first symptoms around other times of hormonal change, such as pregnancy (4.5%), and menopause (5.5%)
  • Long delays between onset and treatment: Although Lipedema may appear early in life, the average age of diagnosis is 48 years old, and women sought medical attention 17 years after first noticing symptoms
  • No standard path to diagnosis: Most participants (59%) had received a diagnosis from one or more health care professionals. Of these, 63% had received a diagnosis from a non-surgeon medical doctor. About a third (32%) had received a diagnosis from a surgeon
  • Consistent pain: Average daily pain for most participants was five on a 10-point pain scale
  • Top systems are leg heaviness, fatigue, and easy bruising: These symptoms occur with frequency and some severity, with leg heaviness (65%), fatigue (54%), and bruising (50%) reported as being “very severe”
  • Runs in families: Nearly all (94%) of the participants report a family history of Lipedema

The report also found that people with Lipedema experience numerous comorbidities, including obesity, which was self-reported by 73% of participants. Other comorbidities reported include spider veins (48%), Irritable Bowel Syndrome (IBS) (20%), and Ehlers-Danlos Syndrome-Hypermobility (12%).

Lipedema is often misdiagnosed as obesity or lymphedema, but there are important differences between these conditions. In obesity, fat occurs throughout the body, while in Lipedema, fat typically occurs in the limbs, sparing the hands and feet. In lymphedema, swelling usually affects only one side of the body, and includes hands and feet. In addition, unlike Lipedema, lymphedema can be diagnosed with imaging or genetic tests.

The Lipedema Foundation partnered with RTI International, a nonprofit research institute based in Triangle Park, NC, to analyze the data. “The First Look Report is a tool that can be used to advance Lipedema awareness, understanding and care,” says Stephanie Peterson, Data Manager, Lipedema Foundation. “The next step is to challenge healthcare professionals to recognize and treat Lipedema and stop dismissing patients when they seek care.”

The Lipedema Foundation engages researchers to develop and expand the Lipedema scientific community. In recent years, due to growing awareness and interest in the condition, there has been a surge in Lipedema research, with the Lipedema Foundation funding about 20% of the work published.

“An acceleration of research is needed as we seek to evaluate existing treatments,” says Kartt. “A future of accessible and evidence-based approaches to diagnosing Lipedema requires a better understanding of the disease and the various impacts of Lipedema on patient lives.”

Learn more about the LF Registry findings and download a free copy of the 16-page report. Watch the What is Lipedema? video to learn more about the condition.

ABOUT THE LIPEDEMA FOUNDATION: The Lipedema Foundation is a private, non-fundraising foundation established in 2015 to define, diagnose and develop treatments for Lipedema. It has awarded more than $11 million in the US and internationally to date and maintains the Lipedema Foundation Registry.

ABOUT LIPEDEMA: Lipedema is a chronic medical condition primarily impacting women and characterized by a symmetric buildup of adipose tissue (fat) in the legs and arms, often with pain and, at advanced stages, impaired mobility. It is frequently misdiagnosed as obesity or lymphedema, though Lipedema is resistant to exercise and diet. Lipedema is widespread, affecting millions of adolescent and adult women, but is vastly underdiagnosed. Awareness is increasing; progress includes the American College of Cardiology and publication of a standard of care in the United States.

Find out more at lipedema.org.

Share article on social media or email:

Newly FDA Approved Device to Treat Urinary and Bowel Dysfunction Now Available in Oklahoma City


Dr. Arielle Allen.

93% of patients experienced clinically significant symptom improvements at two years post-implant.

Dr. Arielle Allen, D.O. announced today the availability of Axonics Therapy—a long-lasting and clinically proven solution that provides symptom relief for patients suffering from overactive bladder, bowel incontinence, and urinary retention. Today, millions of people worldwide suffer from these chronic and debilitating symptoms.1

The Axonics Therapy works by providing gentle electrical stimulation (sacral neuromodulation) to the nerves that control the bladder and bowel, restoring normal communication and improving symptoms.

The Axonics System offers a long-lived miniaturized neurostimulator that is approximately the size of a quarter. The rechargeable device is implanted into the pelvic area during a minimally invasive outpatient procedure. It is qualified to last 15 or more years in the body eliminating the need for repeat surgeries over the patient’s lifetime.

Until today, the only other product available required replacement surgery every three to five years due to battery depletion and removal of the implanted device if an MRI was required. Patients are provided with a discreet easy-to-use remote control that can be used to manage their therapy.

Benefits of Axonics Therapy


  • Clinically proven to help people regain urinary and bowel control. 2
  • 93% of patients experienced clinically significant symptom improvements at two years post-implant. 2
  • Designed to provide patients with long-lasting relief.
  • Allows patients to undergo full-body MRI safely without having to explant the device.
  • High patient satisfaction at two years. 2
  • 94% of patients were satisfied with their therapy. 2

I see women every day that suffer from urinary and bowel symptoms for which the Axonics device could drastically improve! This device is low-maintenance and long-lasting. It is easy for patients to use and gives women more confidence to enjoy life as it is meant to be enjoyed without fear of urinary or bowel accidents! This is why I’m excited to offer this new technology!

Individuals can contact the main phone number of Urogynecology of Oklahoma to schedule an interview: 405-400-8188.

About Dr. Arielle Allen

Dr. Arielle Allen, D.O. is a fellowship-trained Urogynecologist, board-certified in Female Pelvic Medicine and Reconstructive Surgery, specializing in female pelvic health. She earned her Medical Degree from Oklahoma State University and completed both her residency and fellowship training at the University of Oklahoma.

Dr. Allen has dedicated her training to the health and well-being of women. Her education and training have given her the tools to help women live happier, healthier, and more fruitful lives. She strives to educate women about the urinary and gynecologic changes associated with aging and can provide specialized treatment plans for female pelvic-related problems.

No two women are alike. We all come with our own special set of circumstances, needs and concerns. Dr. Allen makes it her goal to know her patients individually. Every detail matters.

About Urogynecology of Oklahoma

Urogynecology of Oklahoma was founded in Oklahoma City in 2015. Over the past seven years, they have served thousands of patients searching for a solution to their problems. They are now located in their beautiful new building at 11100 Hefner Pointe Dr. in Oklahoma City.

References:

1. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132-1138.

2. Pezzella A, McCrery R, Lane F, et al. Two-year outcomes of the ARTISAN-SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system [in press]. Neurourol Urodyn. 2021.

Share article on social media or email:

Applying Patient-Centric Practices Throughout Clinical Development, Upcoming Webinar Hosted by Xtalks


The featured speakers will share their extensive practical experience across the clinical development process in implementing PFDD.

Modern clinical trials have become incredibly complex, often requiring extensive assessments on niche populations. With studies placing such a significant burden on patients it is no surprise that recruitment and retention of trial participants remains an ongoing challenge. While clinical trials may never be easy, patient-centric study design, incorporating patient feedback and operationalization with the right technologies can alleviate barriers and increase accessibility.

The US Food and Drug Administration (FDA) Patient-Focused Drug Development (PFDD) program is a systematic approach to engaging patients throughout the drug development process. While nearly everyone agrees with the aspirations of PFDD, practically implementing patient-centric approaches across the clinical development process can present real obstacles. These include early challenges like creating or identifying the right clinical outcome assessment and integrating them into the overall study design, listening to patients early and often for protocol refinement and recruitment, and operationalizing studies that ultimately work for the needs of a specific population. The featured speakers will share their extensive practical experience across the clinical development process in implementing PFDD.

Join this webinar to hear about strategies for developing patient-centric clinical outcome assessment and trial designs, methods for listening to patients throughout a trial and practical guidance on operationalizing a study for patient-centricity.

Join experts from THREAD Research, Fabio Gratton, Cofounder and CEO of inVibe Labs, a Division of THREAD; Noah Goodson, PhD, Director, Consulting, Decentralized Study Design Lead; Kim McLean Boericke, Chief Delivery Officer; and Stefan Cano, Chief Scientific Officer, Modus Outcomes, a division of THREAD, for the live webinar on Wednesday, September 28, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Applying Patient-Centric Practices Throughout Clinical Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Decentralized and Hybrid Clinical Trials — Importance of Interoperability and Partnership, Upcoming Webinar Hosted by Xtalks


Join this webinar for ways to engage and retain patients and the factors to consider for implementing a successful end-to-end solution when evaluating or adopting technologies used in decentralized/hybrid clinical trials.

Technologies providing capabilities to conduct decentralized and hybrid clinical trials have existed for many years, but historically companies were slow to adopt them. The COVID-19 pandemic changed the landscape of clinical trials, accelerated the adoption of tools and highlighted the importance that interoperability and partnership play in achieving a successful end-to-end solution.

Decentralized aspects of clinical trials are becoming more widespread in the industry today and will continue to be commonly adopted through a hybrid approach. Technologies to support televisits, electronic consent and patient-reported outcomes are now a necessity.

The need for these and evolving technologies will continue to grow for many reasons. There is a rising movement in people, who work from home, moving out of cities, where most clinical research sites exist. People are living longer, and our aging population tends to have a more difficult time getting to a clinic regularly to be involved in a clinical trial. Most clinical trials are conducted on white males, and the industry has recognized the need to reach a more diverse population. This includes more research on women and people of different races and ethnic backgrounds. Many potential participants may not live close to clinical research sites or may not be able to frequently miss work to participate in a clinical trial. Recruiting a diverse population and decreasing patient drop-out rates requires making participation in clinical trials easier.

This webinar will focus on the various solutions needed for conducting decentralized clinical trials (DCTs)/hybrid clinical trials, including the interoperable technologies and partnerships required to provide the best patient experience.

Join this webinar for ways to engage and retain patients and the factors to consider for implementing a successful end-to-end solution when evaluating or adopting technologies used in decentralized/hybrid clinical trials.

Join Laura Acosta, Vice President Product Management eClinical Suite, Visit Anju, for the live webinar on Thursday, September 29, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Decentralized and Hybrid Clinical Trials — Importance of Interoperability and Partnership.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

New Options for Avoiding a Dedicated TQT Study — The Impact of the New ICH E14/S7B Revisions, Upcoming Webinar Hosted by Xtalks


They will then share their impressions on the new opportunities that these revisions provide for drug development, as well as some thoughts on the as yet unresolved issues that will only become clarified over the next few years as regulators become more familiar with nonclinical data.

In this webinar, the featured speakers will be discussing the impact of the new ICH E14 and S7B revisions and how they impact clinical trials. Dr. Darpo will be discussing the new E14 material and will share the practical implications and use cases. Dr. Kleiman will discuss the S7B changes from the view of a clinician, rather than as a nonclinical safety pharmacologist. They will then share their impressions on the new opportunities that these revisions provide for drug development, as well as some thoughts on the as yet unresolved issues that will only become clarified over the next few years as regulators become more familiar with nonclinical data.

Join this webinar to understand the recent changes to ICH E14 & S7B revisions.

Join experts from Clario, Robert Kleiman, MD, Vice President, Cardiology & Chief Medical Officer; and Borje Darpo, MD, PhD, Chief Scientific Advisor, Cardiac Safety, for the live webinar on Friday, September 30, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit New Options for Avoiding a Dedicated TQT Study — The Impact of the New ICH E14/S7B Revisions.

ABOUT CLARIO

Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralised and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario’s Trial Anywhere™ solutions have been powering hybrid and decentralized clinical trials (DCT) for over 20 years, enabling sponsors to collect high-quality endpoint data from any modality or location, all while improving the patient experience and diversity. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory for over 5m patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.

For more information, go to Clario.com or follow us on LinkedIn and Twitter.

Clario Media Contact

Duncan Cantor

Sr. Director, Corporate Communications

media@clario.com

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:



DevCycle and Macrometa Announce Infrastructure Partnership Streamlining Feature Flagging in Serverless Environments


DevCycle, the leader in innovative solutions to feature flagging, announced an industry first today, Edge Flags, a globally replicated edge storage engine that simplifies feature management.

Together with DevCycle’s new infrastructure partner, Macrometa, an edge computing and data platform, the two organizations are revolutionizing feature flags in serverless edge computing environments.

Edge Flag’s SDK and APIs make it easy to save user data to the edge and use it for feature targeting. This data is available whenever it is needed, whether that data would typically be accessible or not. This ability to store and employ data for feature targeting even in cases where it isn’t normally accessible is a revolutionary improvement in the feature management market.

“DevCycle’s Edge Flags make custom data pipelines unnecessary. Data can be saved to DevCycle whenever it is available and accessed by our lightning fast APIs to make near instantaneous flagging decisions. All engineers need to send to DevCycle is a User ID to be able to leverage that data, making its use simple,” said Aaron Glazer, CEO of DevCycle.

To get started with Edge Flags, teams simply need to mark data to be saved to the cloud. This data will then be instantly available for future targeting decisions. Along with the support of our infrastructure partner, Macrometa, architecting data pipelines is no longer complex for teams. DevCycle’s SDKs and APIs make this easy, by instantly committing the desired data to our databases at the edge.

“We’re thrilled to be partnering with DevCycle to make it easy for teams to launch features quickly and with confidence,” said Justin Johnson, Director of Developer Product & Relations at Macrometa.

If you’re looking for a feature management platform that can help you launch features faster and with less risk, DevCycle is the perfect solution. Our platform is easy to use and can handle even the most complex scenarios. Try it for free and see for yourself.

About DevCycle

DevCycle is the leading feature management platform trusted by companies of all sizes to improve their software development process and ship features faster with confidence. DevCycle offers feature flags, A/B testing, and integrations with popular development tools like GitHub, Jira, and Slack. For more information about DevCycle visit https://devcycle.com/ and sign up for a free account.

About Macrometa

Macrometa is a secure, global data platform and NoSQL database with integrated pub/sub, stream processing, and search. Create real-time apps and APIs in minutes – not months. Learn more at https://www.macrometa.com/.

Share article on social media or email:

LensDirect Launches Exclusive Line of Performance Eyewear in Collaboration with Fitness Lifestyle Influencer Brian Mazza


Collab: LensDirect x Brian Mazza Performance Sunglasses

We’re committed to staying the course with all the vision care essentials, but we know there is an immeasurable amount of brand excitement that comes with partnering with the right influencers that have the right audience in a specific space. – Ryan Alovis, CEO of LensDirect

LensDirect, a leading online retailer of vision care products, launched a limited-edition line of unisex performance sunglasses, partnering with multi-industry entrepreneur and trendsetter, Brian Mazza.

The 30-year-old direct-to-consumer optical pioneer has developed, in collaboration with Mazza, two unique styles called Flow and Potenza, that have been engineered to perform. The exclusive line of sunglasses come standard with premium features like impact/shatter resistant lenses, UV protection and anti-glare. In addition to the durable lenses, the sunglasses are light-weight and have anti-slip technology built onto the nose pads.

“As a Fitness Entrepreneur, I’m committed to performing at the highest level, and when you combine that focus with LensDirect’s long-history of optical excellence, we’re able to usher in a new world of eyewear.,” says Brian Mazza, Founder of HPL Training. “I’m excited to collaborate with LensDirect, bringing to the market an exciting collection of stylish and affordable frames that have been engineered to perform.”

LensDirect chose Brian Mazza for its first collab to take on the challenge of creating frames that stand up to the work-hard, play-hard lifestyle Brian and many other active individuals lead. Whether he’s embarking on his next ultramarathon, pushing himself with a rigorous workout, or just living life with his family, Mazza embodies what high performance means while his 426K Instagram followers take note.

Styles include:

Flow ($74) – available in Fade Blue & Sunset White: High performers know what it’s like to be in the “flow,” where they become one with their craft in a state of pure focus. The Flow sunglasses wrap around the eyes, with mirrored lenses standing between you and the annoyances, the haters, the quitters, and anything else that could keep you from achieving your goals.

Potenza ($74) – available in Azure Sky Blue, Blaze Red, Chroma Green, Ibiza White, Radiant Pink: The Potenza’s full wraparound frames are built to hold up under whatever challenge you take on next. Brian Mazza has hit the heights in fashion, hospitality, fitness, and corporate speaking, and these are the frames he’s wearing into his next round of adventures. Whatever you have in store for these frames, they’re ready for it, and they’re ready for you.

The Mazza collaboration is the latest milestone for LensDirect. The New York-based vision care company has launched a slew of initiatives and has become a regular on the Inc. 5000 list of fastest growing private companies. Over the summer they unveiled a Breakfast at Tiffany’s-inspired sunglasses frame, the Holly, that instantly became a best seller and was touted as the “sunglasses that you have to have” by People Magazine.

“We’re committed to offering the vision care essentials, but we know there is an immeasurable amount of brand excitement that comes with partnering with a leading influencer that has a dedicated audience in a specific space,” says Ryan Alovis, CEO of LensDirect.com. “When we decided to launch a line of performance sunglasses, we knew Brian Mazza was the only choice.”

The LensDirect x Brian Mazza are on sale for $74 and come with free shipping. They are currently being sold exclusively on LensDirect.com.

About LensDirect.com

Founded in 1992, LensDirect.com is one of the largest independent online retailers of vision care products. LensDirect offers name-brand contact lenses, their own lines of eyewear, a lens replacement service (same frames, new lenses), and vision care accessories. The New York-based company operates with a customer first mentality and because of that, they’re rated Excellent by Trustpilot with nearly 6000 reviews.

For more information on LensDirect.com, visit http://www.lensdirect.com.

Share article on social media or email:



Ideal Option Opens Second Addiction Medicine Clinic in Bismarck


Ideal Option, a national leader in evidence-based outpatient treatment for addiction to opioids – such as fentanyl, heroin, and oxycodone – methamphetamine, alcohol and polysubstance, is now welcoming patients at its second clinic in Bismarck. The beautiful new clinic, located at 221 W Divide Ave, offers primarily buprenorphine-based medication-assisted treatment led by an onsite addiction medicine specialist delivering personalized, face-to-face patient care.

Due to its cheap, potent and plentiful supply, fentanyl, a dangerous and highly addictive synthetic opioid, has begun to take over the illicit drug scene in North Dakota.

“As a department and as an agency, statewide we are seeing a substantial increase in the amount of fentanyl arrests and the amount of possessions,” says Bismarck Police Lieutenant Jeff Solemsaas. Bismarck police seized nearly 10,000 pills containing either fentanyl or oxycodone in 2021.

Ideal Option recently released its 2021 Annual Patient Outcomes Report for patients living in North Dakota. The report shows fentanyl positive rates at enrollment were up by 95% displacing heroin positive rates which were down by 49% compared to 2020. The data also support the effectiveness of treatment. Among patients who remained in treatment with Ideal Option during 2021, urine drug testing shows:

  • 98% less fentanyl use
  • 93% less total opioid use
  • 95% less heroin use
  • 82% less methamphetamine use
  • 60% less benzodiazepine use

The new clinic is Ideal Option’s second location in Bismarck and comes at a time of desperate need for expanded access to evidence-based treatment from experienced providers. Ideal Option has been specializing in addiction medicine using Suboxone® for 10 years and currently operates 81 clinics across 10 states.

“The opioid epidemic is destroying families and communities across the United States, and the Bismarck-Mandan community is not immune,” said Carissa Cornell APRN, FNP, addiction medicine specialist for Ideal Option in Bismarck. “Just as an individual’s environment contributes to their addiction, so too does it contribute to a successful recovery. Finding the right atmosphere that offers you the treatment options best suited to meet your needs is the first step toward recovery. By opening a second Bismarck location we can expand our services and help decrease the transportation barriers that affect many.”

The new Ideal Option clinic in Bismarck is open Monday – Thursday, 7:30 a.m. – 6 p.m. and is located at 1221 W Divide Ave, Bismarck, ND 58501.

Most insurance plans are accepted, including Medicare and Medicaid, and patients can typically get started on treatment for fentanyl, heroin, alcohol or other substances within 1-3 business days.

Patients can make an appointment by calling 1.877.522.1275 or visiting http://www.idealoption.com.

About Ideal Option

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped nearly 60,000 patients through a network of 81 office-based medication-assisted treatment (MAT) clinics across 10 states. With a mission to serve under-served communities, Ideal Option accepts all forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.

Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.

In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email:

NYC Dermatologist, Dr. Julie Russak, launches first Anti-Aging Wellness Program of its kind in the U.S.


Dr. Julie Russak, Board-Certified Dermatologist

Dr. Julie Russak, Board-Certified Dermatologist

“The program was designed for patients who want to receive a custom plan on how to approach anti-aging and wellness together.” -Dr. Julie Russak

Julie E. Russak, M.D., FAAD., is a Board Certified Dermatologist, Founder of Russak Dermatology Clinic in Manhattan and specializes in general and cosmetic dermatology, regenerative aesthetic medicine, skin cancer and dermatologic surgery. Dr. Russak has received numerous honors and recognition of her clinical excellence, including being selected as a “New York Super Doctor” by New York Times Magazine.

An Integrative Approach to Aesthetic Medicine and Metabolic Aging on the Cellular Level

The new physician and nutritionist-led program utilizes a 360° approach to aesthetics and longevity, designed to empower patients with the clinical data, tools and treatments to reverse the signs of aging and feel their best. “The program was designed for patients who want to receive a custom plan on how to approach anti-aging and wellness together.”- Dr. Julie Russak

In-house Board Certified Holistic Nutritionist & Celebrity Health Coach, Jennifer Hanway, alongside Dr. Russak, leads all patients through their highly-personalized testing analysis and develops customized nutrition, supplement, lifestyle and aesthetic treatment plans. Jennifer’s deep knowledge of hormonal imbalances, gut health and body composition informs her holistic approach.

“Aging well is the mission of the program, and that requires more than skin deep procedures. We have the ability to reprogram gene expression to increase our healthspan, while resetting our cells to a more youthful state. Benefits of the program include slowing premature aging internally and externally, healthy skin and hair, hormone and metabolism optimization, weight loss, increased lean muscle mass, increased energy levels and mental clarity.” – Jennifer Hanway.

Russak Dermatology Clinic works with leading integrative laboratories, specializing in epigenetic and functional testing including biological age, food intolerance, gut health, micronutrient and hormone panels. “Hormones tell your tissues and organs what to do. A slight imbalance can cause fatigue, anxiety, acne, hair loss, weight change and more. Hormone health is a critical pillar of the program.” -Jennifer Hanway.

A Regenerative Reset

Dr. Russak’s Regenerative Aesthetics menu was designed to go hand-in-hand with the program. It includes therapies such as exosomes, stem cell facelift technology, platelet rich plasma (PRP), IV drips and bio-stimulatory injectables. The clinic carries clinical-grade skincare and nutraceuticals that boost the body’s natural regenerative responses and have secured brand partnerships available to their patients, including health-expert designed, organic meal delivery service, Daily Dose and integrative supplement brand, Nutrafol.

Russak Dermatology Clinic Expansion

The newly expanded aesthetic center will house the Anti-Aging Wellness Program and regenerative aesthetics offerings. The mission of the newly expanded space is to guide patients on how to harness the regenerative power of their own body. Think of your skin’s health, but elevated and enhanced through integrative and cutting-edge aesthetic treatments that address your body’s total wellness, inside and out.

About Dr. Julie Russak

Julie E. Russak, M.D., FAAD., is a Board Certified Dermatologist and Founder of Russak Dermatology Clinic. Dr. Russak serves as Faculty at Mount Sinai Hospital, where she teaches dermatology residents and medical students. Dr. Russak has distinguished herself in the medical community through her clinical research, scientific presentations, publications and aesthetic approach. She attends anti-aging, aesthetic and regenerative medical conferences around the world to incorporate advancements in these fields into her practice. Some notable conferences include the Aesthetic & Anti-Aging Medicine World Congress and the Annual Mount Sinai Winter Symposium “Advances in Medical and Surgical Dermatology”.

Dr. Russak is frequently sought out by beauty editors and industry outlets as an expert contributor, including Good Morning America, NewBeauty, Cosmopolitan, Forbes, and Marie Claire. Dr. Russak serves as a consulting Dermatologist and formulator to clean skincare brand, Covey.

For all marketing and media inquiries, please contact Gabrielle@RussakDermatology.com. Learn more at http://www.russakplus.com and IG: @russakderm

Share article on social media or email:



‘Reasons to review the living will,’ a report from We Help You Legal


living trust Paso Robles

It’s a good idea to review the AHCD at periodic intervals.

The living will, also known as the Advanced Health Care Directive (AHCD) is an important and often overlooked legal document that details medical care wishes. There is no time like now to create one or to review an existing AHCD and We Help You Legal, of Paso Robles legal document assistance service, recently released a report with reasons that indicate it’s time to review the living will.

It’s a good idea to review the AHCD at periodic intervals. Some recommend at least every five years, but any life change is a good time, especially a divorce. Married couples often designate one another as the person to make health care decisions on behalf of the spouse who is unable to do so. Divorce has a way of changing the dynamics between formerly married partners and many prefer to make a clean separation of personal affairs. Medical care and end-of-life decisions are among some of the most important personal affairs. Revisiting the AHCD and making necessary changes is critical to make sure that final wishes are honored.

Another reason to periodically review the AHCD, reports the Paso Robles living trust document assisting service is because advances in medical care are happening at a much speedier rate in the past 10 to 15 years. Today there are diagnostic tools and life-saving measures that are more advanced and might make a difference in the quality of care. The AHCD also specifies organ donation and burial or cremation.

In addition to the AHDC and a medical power of attorney, there may be a durable power of attorney that authorizes the former spouse to handle financial matters such as paying bills and making financial decisions including selling property. It’s important to make sure that trustworthy people are authorized to make medical and financial decisions on your behalf. It’s also possible to designate two or more people so that the responsibilities are shared.

It’s not always necessary to pay an attorney to review the AHCD, powers of attorney, and other associated documents like a will and a living trust. Many who are comfortable doing their own review and updates only need professional assistance to help make sure any changes have been made correctly and all the required filings and recordings are timely. The living trust assisting services from Paso Robles or San Luis Obispo, We Help You Legal can help.

We Help You Legal is not a law firm and cannot give legal advice or represent clients in court, however, as California Licensed Document Assistants, the service can assist with a variety of legal documents including adoptions, name changes, living trusts, living wills, divorce, annulment, legal separation, forming a corporation and more.

We Help You Legal has offices conveniently located in Paso Robles and San Luis Obispo. The company is licensed and bonded in California, San Luis Obispo County LDA # 260 Exp. 11/2/22 Bond #65279225. Business License #6893.

We Help You legal is a “self-help” legal document assistance company that provides document preparation without the high cost of an attorney. We Help You Legal, Inc. is not a law firm. We cannot represent you in court, advise you about your legal rights or the law, or select forms for you.

We Help You Legal

720 10th St,

Paso Robles, CA 93446

(805) 237-7770

Share article on social media or email: